Adimarket, a Global Stem Cells Group subsidiary, has been named distributor in Latin America for Bioquark Biologic regenerative medicine products, developed for tissue and organ repair and regeneration.

Global Stem Cells Group subsidiary Adimarket has been named the Latin America distributor for Bioquark, Inc.’s biologic products for the regeneration and repair of human organs and tissues. The announcement is the latest in Global Stem Cells Group’s ambitious expansion plans in Latin America, a commitment made to meet the region’s growing demand for access to regenerative medicine and stem cell therapies.
Bioquark Inc. is focused on the development of biologics that have the ability to alter the regulatory state of human tissues and organs, with the goal of curing a range of chronic diseases, as well as affecting complex tissue regeneration. The biologic regulatory states of human cells, tissues and organs represent the central control processes behind disease, degeneration and aging.

Bioquark’s core program focuses on developing a singular class of substances, termed combinatorial biologics, which take a different approach to reversing underlying disease, degeneration or aging processes, as opposed to only effecting only the symptoms of these conditions.

Combinatorial biologics work at the level of the regulatory genome and are modeled off of biochemical dynamics found in various species that can naturally modify biologic regulatory states to achieve beneficial outcomes, such as complex tissue and organ regeneration, disease reversion, and even biological age reversal.

“The revolutionary work that Bioquark is performing is a perfect fit for Global Stem Cells Group’s vision of the potential that stem cell therapies hold, now and in the future,” says Ricardo DeCubas, Global Stem Cells Group co-founder and Cellgenic CEO.

The collaboration between Global Stem Cells Group, Adimarket and Bioquark is another step toward GSCG’s commitment to expanding its presence in communities that need and deserve access to cutting-edge regenerative medicine, not only in Latin America but also worldwide.
For more information visit the Global Stem Cells Group website, email bnovas@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine. Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. Each of GSCG’s six operating companies focus on a separate research-based mission; the result is a global network of state-of-the-art stem cell treatments and facilities.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Bioquark, Inc.
Founded in 2007, Bioquark, Inc. is a life sciences company developing proprietary combinatorial biologic products for both the regeneration and repair of human organs and tissues. The company’s core program is focused on the development of novel combinatorial biologics capable of directly remodeling diseased, damaged, or aged tissues, and creating micro-environments that induce efficient and controllable regeneration and repair.

Through an innovative approach to biologic regulatory state modification, Bioquark researchers are capable of creating dynamics in mature tissues that are normally only seen during human fetal development, as well as during limb and organ regeneration in organisms like amphibians.
Developed as biologics, Bioquark’s therapeutics will be more amenable to existing regulatory pathways than other cell technologies, and able to circumvent many limitations in the industry’s current offerings.

About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.

Global Stem Cells Group and its subsidiary Stem Cell Training announce the company’s first European symposium on cellular and regenerative medicine, to be held in Barcelona, Spain Oct. 9-10, 2015. The symposium will be hosted at the Official Medical College Of Barcelona by J. Victor Garcia Gimenez, M.D., of Therapeutic Confrontations.

Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
stem cell therapies,EuroMedicom,stem cell medicine,global stem cells group,medical tourism,cellgenic,
Stem Cell Training

We have put together a program designed to include cellular communication pathways, influence of the niche in stem cell behavior, and recent studies and supporting investigational protocols for clinical applications.
Miami, FL (PRWEB) May 26, 2015

Global Stem Cells Group and Stem Cell training, Inc. have announced plans for the company’s first cellular and regenerative medicine symposium in Barcelona Spain Oct. 9, 2015, followed by a full day, hands-on stem cell training class Oct. 10. The event will be hosted by J. Victor Garcia Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona.

In response to the medical community’s increasing interest in regenerative medicine and recent advances in cellular therapies, Global Stem Cells Group, CONFTERA, and their faculties have put together a program designed to include cellular communication pathways, influence of the niche in stem cell behavior, and recent studies and supporting investigational protocols for clinical applications. Theory portions of the symposium will be dictated by relevant members of both faculties.

The symposium will be followed by a full day, hands-on training session on Oct. 10 to provide participating physicians with state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells, along with clinical protocols.
The symposium will be held in the auditorium of the Official Medical College Of Barcelona.

For more information, visit the Global Stem Cells Group website or the Stem Cell Training, Inc. website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337,

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Stem Cell Training, Inc.:
Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

About J. Victor Garcia Gimenez, M.D. and CONFTERA:
J. Victor Garcia Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA), is a specialist in orthopedic surgery and practices cosmetic medicine and surgery, anti-aging medicine, and esthetic therapies in Barcelona.

Garcia Giminez received a Bachelor of Medicine and Surgery degree from the Autonomous University of Barcelona in 1977, and a Specialist in Orthopedic Surgery degree in 1980, also from the Autonomous University of Barcelona. He later received a diploma in Cosmetic Medicine and Surgery from the Autonomous University of Barcelona before attending the National College of Medicine and Aesthetics (Collège National de Médecine et Esthetique) in Montlhéry, France. Garcia Giminiz received a master’s degree in Dermopharmacy and Cosmetology at the University of Barcelona, and a training diploma in Cosmetic Medicine and Surgery at the Medical College of Barcelona; he received a Master’s degree in Cosmetology, Esthetic Medicine and physiological aging from the University of Barcelona.

Garcia Giminiz is the President of the Spanish Society of Medicine and Cosmetic Surgery; Co-director of the UAB-SEMCC; Chairman for Spain of the International Academy of Cosmetic Surgery and a number of additional medical and professional boards.

Global Stem Cells Group and its subsidiary Stem Cell Training, Inc. have announced three upcoming dates for the company’s Adipose and Bone Marrow Stem Cell Training Course for medical professionals in Miami. Courses will be held May 2-3, May 9-10 and June 15-16, 2015.
All three scheduled classes provide the same intensive, hands-on training that covers the latest technology and procedures in adipose and bone marrow stem cell therapy. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement.
Day one of the course will encompass educational lectures on basic stem cells science and the development of adipose stem cells in the treatment of degenerative diseases. Curriculum will include, “Introduction to stem cells II;” “Stem Cell Biology III;” “Embryonic Stem Cells IV;” “Adult Stem Cells V;” “Platelet Rich Plasma VI;” “Adipose Stem Cells and Degenerative Diseases VII;” “Liposuction and Stem Cells VIII;” “Stem Cell (SVF) Isolation Technique IX” and “Regulatory Issues and Standards of Practice.”
Day two will demonstrate live cases to show how the physician performs the procedure in an office setting. Curriculum will include: “Adipose Harvesting Techniques II;” “Stem Cell Isolation Techniques III;” “PRP Processing Demonstration IV;” “Stem Cell Injection Technique V;” “Adipose Harvesting VI;” “Stem Cell Isolation Techniques VII” and “Stem Cell Injection Techniques.”
The May 2-3 course and the June 15-16 course will be held in Miami; the May 9-10 course will be held in Boca Raton and will feature a special guest instructor.
The Adipose and Bone Marrow Stem Cell Training Course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctor’s office by teaching effective, in-office regenerative medicine techniques.
Read More at: Official PR Release

GlobalStemCellsGroup.com has announced plans to participate in the IIIº World Congress on Clinical and Esthetic Research May 16 and 17, 2015. More than 500 physicians from Argentina, Mexico, Peru, Ecuador, Uruguay, El Salvador, Venezuela, Spain, Chile, Cuba and the U.S. are expected to attend, including specialists in aesthetic medicine, dermatology, plastic surgery, cosmetology, physiotherapy, nutrition and dentistry.
Following the conference, Global Stem Cells Group will conduct an intensive, hands-on course on stem cell harvesting, isolation and re-integration for qualified practitioners.
Hosted by the Association of Clinical and Esthetic Research (ACER), the event’s organizing committee has designed a program highlighting nationally and internationally renowned physicians and esthetic practitioners as featured speakers. The goal is to exchange clinical and scientific findings, and to grow academically.
The event will be held at the Hotel Amerian in the City of Villa Carlos Paz, Córdoba.
For more information visit the IIIº World Congress on Clinical and Esthetic Research website.
Read More at: Official PR Release

Global Stem Cells Group Advisory Board member Alfredo Hoyos, M.D., will be a featured speaker at The Aesthetic Meeting May 14-19, 2015. Hoyos will promote the company’s new stem cell assisted fat transfer training course for medical professionals.
Global Stem Cells Group today announced plans to attend The Aesthetic Meeting 2015, an annual gathering of aesthetic medicine experts and innovators. GSCG Advisory Board member Alfredo Hoyos, M.D., is scheduled to introduce the company’s brand new training course that combines facial fat transfer injection techniques with adipose-derived stem cell techniques.
The course is designed to address the primary issues that concern patients in the aesthetic field, including facial aging caused by volume loss.
The Aesthetic Meeting is one of the aesthetic surgery industry’s biggest annual events, attracting leading educators, researchers and practitioners from around the world to discuss evidence-based medicine in aesthetic plastic surgery. According to organizers, it is an opportunity to meet with physicians who specialize in aesthetic plastic surgery of the face and body, and learn what advances are being made in the aesthetics field. This year’s meeting will also focus on what to expect beyond 2015 in the world of aesthetic and anti-aging medicine.
Dedicated exclusively to aesthetic surgery and cosmetic medicine education, The Aesthetic Meeting will offer attendees an array of new techniques, key research findings, and helpful information that physicians can apply in their own practice. The Aesthetic Meeting 2015 features a number of special presentations, panels and papers by surgeons with vast experience in aesthetic surgery. Additionally, you’ll gain valuable insights and pearls of wisdom from our international colleagues, as they often have the opportunity to implement new therapies, devices and techniques before they reach the U.S.
The Aesthetic Meeting 2015 will be held at the Palais des Congrès de Montréal in Montréal, from May 14 – 19, 2015. For more information, visit the The Aesthetic Meeting website, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305.224.1858.
Read More at: Official PR Release

Global Stem Cells Group will attend the world-class GTCbio conference at the Hyatt Regency Boston Hotel, April 27-29. The event will showcase the latest developments in all areas of regenerative medicine, stem cell research and business.
Global Stem Cells Group has announced plans to attend the GTCbio Stem Cell Summit 2015 April 27 – 29, 2015 in Boston. This world-class summit will present the latest developments in all areas of stem cell research including applications, biology, medicine, regulations, and the business of stem cells and regenerative medicine.
The conference will address recent developments in pre-clinical and clinical trials, as well as translational research in stem cell therapies, regenerative medicine, tissue engineering, stem cell reprogramming and regulatory guidance. There will be an additional focus on business opportunities in stem cell medicine and its challenges, and discussions on potential strategies for overcoming these challenges.
The GTCbio Summit includes two parallel conferences with joint sessions on stem cell research in the diabetes space, and stem cell therapies from bench to bedside. Both conferences will also feature a lineup of 34 distinguished speakers from a broad spectrum in the medical community. Keynote speakers for both conferences include Masayo Takahashi, MD, PhD, CDB Ophthalmologist, Center for Developmental Biology; Douglas Melton, PhD, Professor & Investigator, Harvard Medical School, and Rudolf Jaenisch, MD, Professor of Biology, Massachusetts Institute of Technology.
Conference A: The 12th Stem Cell Research & Regenerative Medicine Conference discussion topics include:
Cells for Therapeutic Development & Drug Discovery
Advances in Adult & Pluripotent Stem Cells
Tissue Engineering
Immunotherapy: Revolution in Cancer Treatments
Joint Session: Regulatory Challenges in Cell Therapy
Conference B: The 4th Stem Cell Product Development & Commercialization Conference discussion topics include:
Manufacturing & Product Development
Challenges in Developing Clinical Efficacy
Funding Opportunities
Commercialization: Creating Sustainable Business Models
Joint Session: Regulatory Challenges in Cell Therapy
The GTCbio Summit 2015 will be held at the Hyatt Regency Boston Hotel. For more information, visit the summit website. To learn more about Global Stem Cells Group, visit the GSCG website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
Read More at: Official PR Release

Global Stem Cells Group has announced an exclusive representative contract with Chilean health management, development and biotechnology company Consortia Innovas, SA.
Global Stem Cells Group, Inc. has signed an exclusive representative contract with Consortia Innovas, SA, a Santiago, Chile-based health management, development and biotech company. Founded by entrepreneur Enrique Testart, M.D., Consortia Innovas focuses on helping patients gain access to the latest medical treatments regenerative medicine has to offer.
According to Global Stem Cells Group Founder Benito Novas, Testart searches the globe for innovative stem cell companies that fit in with the Chilean markets, and Global Stem Cells Group turned out to be a perfect fit. Innovas will be in charge of all Global Stem Cells Group divisions and programs in Chile, including patient recruiting through Cellgenic, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket.
Cellgenic, Stem Cell Training and Adimarket are all subsidiaries of the Global Stem Cells Group brand.
“Our main objective is to organize Chile’s first symposium on Stem Cells and Regenerative Medicine in Santiago in early 2015,” Novas says. “Our new alliance with Consortia Innovas will allow us to establish our brand as the leader in regenerative medicine therapies in Chile.”
The first annual Global Stem Cells Symposium is scheduled to take place in Buenos Aires Oct 2, 2014, to be preceded by an intensive two-day hands-on training course in stem cell harvesting, isolation and applications Sept. 27 and 28 at Santiago’s Innovas facilities.
The key to Global Stem Cells Group’s strategy to expand into foreign markets by recruiting local representatives and distributors like Consortia Innovas to help manage the company’s growth in a specific geographic area. Global Stem Cells group requires any company under consideration for the expansion program to have more than five years experience in the health care industry with at least some experience in the field of regenerative medicine .
In addition, geographic alliances require a commitment to a number of stem cell training courses during a one-year period, certification of physicians, and willingness to organize a large medical meeting or symposium in their territory.
About Consortia Innovas SA:
Consortia Innovas SA is comprised of a cluster of organizations designed to address the different needs of a new generation of consumers. With more than 20 years’ experience in the public and private sectors, Consortia Innovas specializes in designing customized B2B and B2C models for each central or regional organization, providing innovative services and diagnostic precision determined by local needs.
Consortia Innovas offers innovative and flexible technological and communication resources that enhance the skills of people in the management, operation and marketing fields. For more information, visit the Consortia Innovas SA website, Email contacto@innovas.cl, or call +56 2 2692 3650.

In conjunction with Regenerative Medicine Arroyo, Global Stem Cells Group has announced plans to hold a hands-on, intensive stem cell training course in Santa Cruz, Bolivia, April 4 and 5, 2015.
Global Stem Cells Group and its subsidiary, Stem Cells Training, has coordinated with Emil Arroyo, M.D. and Horacio Oliver, M.D. to conduct the first of four stem cell training courses planned for Bolivia in 2015. Devised to meet the increasing demand for regenerative medicine techniques in the region, the first adipose derived harvesting, isolation and re-integration training course will take place April 4 and 5, 2015, in Santa Cruz.
The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn the techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to provide physicians with practical stem cell medicine techniques they can use in-office to treat a variety of conditions in their patients.

Global Stem Cells Group will conduct a specialized course for qualified medical professionals on stem cell harvesting, isolation and re-integration on April 11, following the Congress on aesthetic medicine.
GlobalStemCellsGroup.com has announced plans to participate in the 25th annual Argentine Congress of Aesthetic Medicine April 9 and 10 2015. More than 1,000 physicians from around the world will descend on Buenos Aires for the conference to learn and share new findings in aesthetic medicine.
Following the congress, Global Stem Cells Group and Estanislao Janowski, M.D., a plastic surgeon specializing in stem cell application in aesthetic and cosmetic medicine will conduct an intensive, hands-on course on stem cell harvesting, isolation and re-integration, to be held April 11. Janowski, a GSCG faculty member and long-time collaborator is the owner and president of Bioplastica, an aesthetic surgical center featuring the latest stem cell applications in cosmetic and anti-aging medicine.
This will be the third year Global Stem Cells Group participates in the conference, hosted by the Argentina Society of Aesthetic Medicine (SOARME). A soon-to-be-named GSCG faculty member will also deliver a keynote speech to congress attendees.
The international event, which will be held at the Catholic University of Argentina in Buenos Aires, will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. SOAME is a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOAME has the scientific support of the John F. Kennedy University in Buenos Aires and a host of national and international scientific organizations.

The Global Stem Cells Group has established a collaborative alliance with HANK Bioengineering Co., Ltd. of Shenzhen, China.
Global Stem Cells Group.com has announced a newly formed alliance with Shenzhen HANK Bioengineering Co., Ltd. and its Chinese-American founder Mingjie Zhang, M.D., Ph.D. The alliance will establish a stem cells training course in the City of Shenzen, Guangdong Province, China in September 2015.
Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration from 1995 to 2013 in various research positions including National Research Center (NRC) senior associate from 1995 to 1997. In 2012 he earned the Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.
In 2013, Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.
Shenzhen HANK is also a biotechnology service provider committed to the development and application of multiple immune cell therapy systems. The company has up to 20 cell therapy products of 4 series approved by the CFDA, including lymphocyte culture medium (NK, CTL and Treg cell in vitro culture reagents), lymphocyte serum-free culture medium, lymphocyte separation media, and lymphocyte freezing medium.
“Dr. Zhang and HANK Bioengineering will work seamlessly with our research, product development and education programs,” says Benito Novas, Global Stem Cells Group CEO. “This is a great opportunity for us to expand into China and work with one of the world’s most accomplished cell therapy researchers in his certified, cutting-edge cell biology laboratories.”